Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.

Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Investor Relations

Press Releases

Press Releases

    Date Title and Summary Additional Formats
    Toggle Summary Vericel Reports First Quarter 2018 Financial Results
    Record First Quarter Revenues of $18.0 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial
    View HTML
    Toggle Summary Vericel to Report First-Quarter 2018 Financial Results on May 8, 2018
    CAMBRIDGE, Mass. , April 24, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2018 financial results and
    View HTML
    Toggle Summary Vericel to Present at the 6th Annual Cell & Gene Therapy Investor Day
    CAMBRIDGE, Mass. , April 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 6 th Annual
    View HTML
    Toggle Summary Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years
    CAMBRIDGE, Mass. , March 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of results from the MACI ® (autologous cultured chondrocytes on porcine collagen
    View HTML
    Toggle Summary Vericel to Present at the 17th Annual Needham Healthcare Conference
    CAMBRIDGE, Mass. , March 13, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 17 th Annual
    View HTML
    Toggle Summary Vericel to Host Analyst and Investor Day on April 11, 2018
    CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it will host an Analyst and Investor Day on April 11, 2018 in New York City from 8:30 a.m.
    View HTML
    Toggle Summary Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
    CAMBRIDGE, Mass. , March 09, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel , chief financial officer and VP of corporate development, will present the latest
    View HTML
    Toggle Summary Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance
    Record Quarterly Revenues of $23.4 Million Represent a 41% Increase Over Fourth Quarter 2016 Positive Operating and Net Income Reported for the Fourth Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a
    View HTML
    Toggle Summary World Champion Swimmer and Twelve-Time Medalist Dara Torres Partners with Vericel for the ‘It’s Your Move’ Campaign
    Campaign Aims to Empower Patients with Knee Pain to Seek Treatment CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that world champion swimmer,
    View HTML
    Toggle Summary Vericel to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference
    CAMBRIDGE, Mass. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 13th Annual
    View HTML

    Day High:
    Day Low:
    Volume:
    on
    Data Provided by Refinitiv. Minimum 15 minutes delayed.